Holm & Halby expands its business:

As of 1 December 2025, Holm & Halby has acquired Pharmacold A/S, a Danish company specialising in refrigeration solutions for the pharmaceutical and healthcare sectors. The acquisition is part of a strategic initiative to strengthen the company’s position within temperature-controlled installations. The transaction was formally completed by Holm & Halby’s parent company, AddLife, which places Pharmacold as a new subsidiary under Holm & Halby.

Pharmacold has, for many years, delivered specialised solutions for temperature-controlled storage, including the installation and servicing of cooling and freezing systems, climate units and mobile low-temperature equipment. The company has established a strong foothold in GxP-regulated environments, where the demands for operational reliability and comprehensive documentation are high.

Through the acquisition, Holm & Halby adds dedicated refrigeration expertise that complements the company’s existing ColdStorage activities. Holm & Halby’s aim is to offer a broader and more integrated portfolio of solutions to the pharmaceutical and life-science sectors, where the need for validated, temperature-critical systems continues to grow.

Pharmacold will continue as an independent company with its current organisation and operating model, while being commercially and technically integrated into Holm & Halby. Pharmacold’s founder, Bjarne Nordbjerg, sees the acquisition as a development that opens new opportunities for the company and its customers. In the press statement, he emphasises that Holm & Halby’s market position and technical environment provide a strong foundation for Pharmacold’s next phase.

Holm & Halby CEO, Morten Dyrner, describes the acquisition as a natural step in the company’s strategy. According to Dyrner, Pharmacold’s specialised competencies strengthen Holm & Halby’s role at the intersection of laboratory operations, production environments and technical infrastructure — all areas where the requirements for documented temperature-controlled processes continue to increase.

AddLife, which owns Holm & Halby, expects the acquisition to have a slightly positive impact on earnings per share in the current financial year.

With the acquisition, Holm & Halby takes another step towards expanding its overall offering to the life-science sector, where both research facilities and production units are increasingly seeking integrated solutions capable of handling complex, process-critical temperature requirements.